Lovrdu Pyreddy, MD
Pulmonary Disease · Fresno, CANPI 1952334583
Payments from drug & device makers
Across 641 payments — averaging $17.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$2K
- Philips North America LLC$1K
- Boehringer Ingelheim$967
- Actelion Pharmaceuticals US, Inc.$523
- Insmed, Inc.$432
- plus $4K from 34 others
What the payments were for
- Food & beverage$11,19899%
- Education$1281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 197 | $2,255 |
| AstraZeneca | 88 | $1,944 |
| Philips North America LLC | 55 | $1,225 |
| Boehringer Ingelheim | 56 | $967 |
| Actelion Pharmaceuticals US, Inc. | 21 | $523 |
| Insmed, Inc. | 15 | $432 |
| Merck | 15 | $351 |
| Electromed, Inc. | 29 | $329 |
| Baxter Healthcare | 13 | $301 |
| United Therapeutics Corporation | 13 | $298 |
| Regeneron Healthcare Solutions, Inc. | 11 | $242 |
| Mallinckrodt Hospital Products Inc. | 9 | $239 |
| Grifols USA, LLC | 10 | $239 |
| Sanofi | 10 | $225 |
| Genentech USA, Inc. | 11 | $189 |
| Advanced Respiratory, Inc | 6 | $181 |
| Verona Pharma, Inc. | 10 | $179 |
| Sunovion Pharmaceuticals Inc. | 15 | $149 |
| Mylan Specialty L.p. | 7 | $132 |
| Johnson & Johnson | 8 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $93 |
| Paratek Pharmaceuticals, Inc. | 4 | $87 |
| Pulmonx Corporation | 2 | $75 |
| Amgen | 3 | $57 |
| Teva Pharmaceuticals USA, Inc. | 4 | $56 |
| AbbVie(2 entities) | 3 | $53 |
| Harmony Biosciences LLC | 2 | $52 |
| Bayer | 3 | $48 |
| Fisher & Paykel Healthcare Inc | 2 | $46 |
| Medtronic | 2 | $38 |
| Astellas Pharma US Inc | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Circassia Inc. | 2 | $30 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Gilead | 1 | $16 |
| Resmed Corp | 1 | $16 |
| Ceribell, Inc. | 1 | $16 |
| Nabriva Therapeutics, PLC | 1 | $15 |
| ANI Pharmaceuticals, Inc. | 1 | $14 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,325 in reported general payments places this provider in the 75th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 363 | $272,857 |
| OfevNintedanib Esylate | 14 | $181,698 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 98 | $74,541 |
| Pirfenidone | 24 | $61,048 |
| Breo ElliptaFluticasone/Vilanterol | 117 | $53,769 |
| Spiriva RespimatTiotropium Bromide | 51 | $38,830 |
| Advair HfaFluticasone Propion/Salmeterol | 64 | $25,510 |
| Incruse ElliptaUmeclidinium Bromide | 35 | $15,328 |
| BreynaBudesonide/Formoterol Fumarate | 85 | $12,266 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 350 | $9,876 |
| Roflumilast | 43 | $9,549 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $9,235 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $9,078 |
| SymbicortBudesonide/Formoterol Fumarate | 38 | $8,859 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $8,139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta | $2,255 | $359,142555 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $967 | $237,901102 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,944 | $83,400136 claims |
| Teva Pharmaceuticals USA, Inc.Proair Respiclick | $56 | $64011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Fresno
- Mohamed FayedFresno$1.6M
- Vijay BalasubramanianFresno$740K
- Vijai DanielFresno$471K
- Toby MaherLos Angeles$27.6M
- David PhamWestminster$5.9M
- Andrew WachtelLos Angeles$5.9M
- Aaron WeinbergIrvine$5.1M
- Michael RothLos Angeles$4.5M
- Namita SoodSacramento$3.7M
- Edward FedermanSan Diego$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.